Survey of Ophthalmology
Volume 47, Supplement 1 , Pages S105-S115, August 2002

Bimatoprost and Travoprost:

A Review of Recent Studies of Two New Glaucoma Drugs

  • Dan L. Eisenberg, MD

      Affiliations

    • Shepherd Eye Center, Las Vegas, NV USA
    • ,
  • Carol B. Toris, PhD

      Affiliations

    • Corresponding Author InformationReprint address: Carol B. Toris, PhD, Department of Ophthalmology, 985145 Nebraska Medical Center, Omaha, NE 68198-5145, USA
    • Department of Ophthalmology, University of Nebraska Medical Center, Omaha, NE, USA
    • ,
  • Carl B. Camras, MD

      Affiliations

    • Department of Ophthalmology, University of Nebraska Medical Center, Omaha, NE, USA

Abstract 

Bimatoprost (Lumigan™ [Allergan, Inc, Irvine CA]) and travoprost (Travatan™ [Alcon, Ft Worth, TX]) are two new intraocular pressure (IOP)-lowering drugs for use in patients with glaucoma and ocular hypertension. This review evaluates recent studies comparing these new drugs with timolol and with latanoprost. In each study, the statistical analyses support the conclusion that these agents were more effective than timolol and as effective as latanoprost in terms of their ability to reduce IOP. The side effect profiles for bimatoprost, latanoprost, and travoprost were similar, but with statistically higher occurrences of hyperemia and eyelash growth for bimatoprost or travoprost versus latanoprost or timolol.

Keywords:  bimatoprost, glaucoma, intraocular pressure, ocular hypertension, latanoprost, timolol, travoprost

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by the an unrestricted grant from Research to Prevent Blindness, Inc., New York, NY. Dr. Camras is a Research to Prevent Blindness Senior Scientific Investigator, and a consultant to the Pharmacia Corporation. The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article.

PII: S0039-6257(02)00327-2

Survey of Ophthalmology
Volume 47, Supplement 1 , Pages S105-S115, August 2002

Article Tools

* Image Usage & Resolution